DOI: 10.1016/j.jval.2012.03.933 View full text |Buy / Rent full text

Abstract: and Ն9%, respectively. Compared with placebo, more patients achieved HbA1c Ͻ7% (39.4% vs 24.4%) and Ͻ8% (79.5% vs 60.6%) and fewer patients remained at or worsened to HbA1c Ͼ9% (4.2% vs 13.9%) with dapagliflozin. CONCLUSIONS: Dapagliflozin 10 mg/day reduced HbA1c across all baseline HbA1c categories; greater reductions were seen in patients with higher baseline HbA1c. Substantially more patients attained HEDIS HbA1c categories of Ͻ7% and Ͻ8% and substantially fewer patients remained at or worsened to HbA1c Ͼ9%… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles